Fiscal Year:
2002
Title:
A NOVEL APPROACH TO CARBON-13 BREATH TESTS
Agency:
HHS
Contract:
1R43GM065757-01
Award Amount:
$102,190.00
Abstract:
Stable isotope medical diagnostic breath tests enjoy the advantages of being non-invasive, highly specific to detecting an invading organism or measuring organ function, and usually lower cost than
competing tests. However, having a lower cost is not always sufficient. There
is great financial pressure and incentives to introduce tests that dramatically
reduce health care expenditures. Reverse Isotope Dilution (RID) was developed
to significantly reduce the cost of future breath tests and in the process
increase the array of possible breath test applications.
The novelty of this application is the RID concept of administering a low cost
tracer with an unlabelled substrate probe. The unlabeled substrate probe
dilutes the CO2 excretion curve that would be expected had only the labeled
tracer been administered. The degree to which the curve is modified provides
insight into the functionality of a specific enzymatic pathway. With RID many
different tests can be performed using the same labeled tracer but only
changing the unlabeled probe. The benefits include making breath tests
economically attractive and expanding the possible applications for tracer
tests.
Our long-term objective is to use RID technology to develop a family of
gastrointestinal stable isotope breath tests that are clinically useful and low
cost.
Small Business Information at Submission:
METABOLIC SOLUTIONS, INC.
METABOLIC SOLUTIONS, INC. 460 AMHERST ST NASHUA, NH 03063
EIN/Tax ID:
043077518
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No